Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
32 results
  • Breast Cancer, Head and Neck Cancer, Ovarian Cancer, Cervical Cancer

21-689          Phase I

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

  • Sarcoma, Thyroid Cancer, Lung Cancer, Kidney Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, Liver Cancer, Breast Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Breast Cancer, Endometrial Cancer, Lung Cancer

25-439          Phase I

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants with Selected Advanced Solid Tumors

  • Breast Cancer

24-240          Phase II

A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

  • Bladder Cancer, Breast Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Breast Cancer

24-707          Phase I

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer

  • Prostate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer

23-452          Phase I

A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  • Cervical Cancer, Breast Cancer, Ovarian Cancer, Endometrial Cancer

25-490          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination with other Anticancer Agents in Participants with Advanced Solid Tumors

  • Pancreatic Cancer, Ovarian Cancer, Melanoma, Lung Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Prostate Cancer

25-287          Phase I

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

  • Breast Cancer, Uterine Cancer, Ovarian Cancer, Lung Cancer, Melanoma, Endometrial Cancer, Bladder Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

Showing 1 - 10 of 32 results